MRNA-1010 is under clinical development by Moderna and currently in Phase III for Influenza A Virus, H3N2 Subtype Infections. According to GlobalData, Phase III drugs for Influenza A Virus, H3N2 Subtype Infections have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how MRNA-1010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
mRNA-1010 is under development for the prevention of influenza, including seasonal influenza A H1N1, H3N2 and influenza B yamagata and victoria. It is a quadrivalent vaccine comprising mRNA encoding hemagglutinin (HA) glycoproteins of four flu strains administered intramuscularly. It is an mRNA vaccine being developed based on mRNA expression platform technology.
Moderna operates as a developer of messenger RNA therapeutics. The company develops and discovers drugs that produce proteins or antibodies inside patient cells. Its pipeline includes various drug modalities such as prophylactic vaccines, therapeutic vaccines, intratumoral immuno-oncology, localized therapeutics, and liver intracellular. Moderna through its mRNA therapeutics platform develops and produces human proteins, antibodies, and novel proteins, which help in preventing, treating, and curing diseases. It also develops therapeutics in the areas of infectious disease, rare liver disease, immuno-oncology, and cardiovascular disease. Moderna Therapeutics is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of MRNA-1010’s drug-specific PTSR and LoA scores, buy the report here.